Hematopoietic Cell Transplantation: Blood Cancers

Policy ID: S-272-002

Section: Surgery

Effective Date: September 05, 2022

Revision Effective Date: July 01, 2024

Last Reviewed: May 14, 2024

Applies To: Commercial and Medicaid Expansion

Description

Hematopoietic Cell Transplantation (HCT) involves the intravenous (IV) infusion of allogeneic (donor) or autologous stem cells to reestablish hematopoietic function in individuals whose bone marrow or immune system is damaged or defective. They can be harvested from bone marrow, peripheral blood, or umbilical cord blood and placenta shortly after delivery of neonates.

A variety of blood cancers may be treated with either allogeneic or autologous HCT, including but not limited to:

Amyloidosis:
- Primary; or
Leukemia:
- Lymphoblastic, acute:
  - Adult; or
  - Pediatric; or
- Lymphocytic, chronic; or
- Myeloid, acute; or
- Myeloid, chronic; or
Lymphoma:
- Hodgkin lymphoma; or
- Non-Hodgkin lymphoma;
  - B-Cell; or
  - T-Cell; or
- Small Lymphocytic; or
Multiple myeloma; or
Myelodysplastic Syndromes; or
Myeloproliferative Neoplasms; or
POEMS syndrome; or
Waldenström Macroglobulinemia

Donor lymphocyte infusion (DLI), also called donor leukocyte or buffy-coat infusion, is another type of therapy in which T lymphocytes from the blood of a donor are given to an individual who has already received a hematopoietic cell transplant (HCT) from the same donor. The DLI therapeutic effect results from a graft-versus-leukemic or graft-versus-tumor effect due to recognition of certain antigens on the cancer cells by the donor lymphocytes and the resultant elimination of the tumor cells.

Policy Application

All claims submitted for this policy will be processed according to the policy effective date and associated revision effective dates in effect on the date of service.

Criteria

Acute Lymphoblastic Leukemia (ALL)

Adult ALL

Allogeneic HCT may be considered medically necessary to treat adult ALL when at least ONE of the following clinical criteria has been met:

Individual is in first complete remission for any risk level; or
Individual is in second or greater remission; or
Individual has relapsed or refractory ALL; or
Individual has relapsing ALL after a prior autologous HCT; or
Individual has failed induction therapy; or
Individual has B-cell lineage ALL with marrow relapse while on treatment or within six (6) months of completing treatment; or
Individual has T-cell lineage ALL in first or subsequent remission.

A second allogeneic HCT to treat ALL when relapsed disease occurs more than six (6) months after initial allogeneic HCT may be considered medically necessary.

Note:

High-risk* for relapse may include but are not limited to:

Age older than 35 years; or
Leukocytosis at presentation of:
- Greater than 30000/L (B-cell lineage); or
- Greater than 100000/L (T-cell lineage); or
"Poor prognosis" genetic abnormalities like the Philadelphia chromosome (t[9;22]); or
Extramedullary disease; or
Time to attain complete remission longer than four (4) weeks.

Allogeneic HCT to treat adult ALL not meeting the criteria as listed in this policy considered not medically necessary.

Autologous HCT to treat adult ALL in first complete remission but at high-risk* of relapse may be considered medically necessary.

Autologous HCT to treat adult ALL not meeting the criteria as indicated in this policy is considered not medically necessary.

Pediatric ALL

Autologous or allogeneic HCT may be considered medically necessary to treat pediatric ALL when at least ONE of the following clinical criteria has been met:

In first complete remission and at high risk of relapse; or
In second or greater remissions or refractory ALL.

Allogeneic HCT may be considered medically necessary to treat relapsing ALL after a prior autologous HCT in pediatric individuals.

Autologous or allogeneic HCT not meeting the criteria as indicated in this policy is considered not medically necessary.

Reduced-Intensity Conditioning (RIC) for ALL

RIC allogeneic HCT may be considered medically necessary as a treatment for ALL in individuals who are in complete marrow and extramedullary first or second remission, and who, for medical reasons, would be unable to tolerate a standard myeloablative conditioning regimen.

RIC HCT not meeting the criteria as listed in this policy is considered not medically necessary.

Guidelines for Autologous and Allogeneic HCT in ALL

Indication

Children (Age Less than 18 Years)

Adults (Age Greater or equal to 18 Years)

Allogeneic HCT

Autologous HCT

Allogeneic HCT

Autologous HCT

First complete response, standard-risk

First complete response, high-risk

Second complete response

At least third complete response

Not in remission

ALL: acute lymphoblastic leukemia; C: clinical evidence available; HCT: hematopoietic cell transplantation; N: not generally recommended; S: standard of care.

Acute Myeloid Leukemia (AML)

Allogeneic HCT using a myeloablative conditioning regimen may be considered medically necessary to treat ANY of the following conditions:

Poor- to intermediate-risk AML in first complete remission CR1 (see table below); or
AML that is refractory to standard induction chemotherapy but can be brought into CR with intensified induction therapy; or
AML that relapses following chemotherapy-induced CR1 but can be brought into CR1 or beyond with intensified induction chemotherapy; or
AML in individuals who have relapsed following a prior autologous HCT but can be brought into CR with intensified induction chemotherapy and are medically able to tolerate the procedure.

Allogeneic HCT using a reduced-intensity conditioning regimen may be considered medically necessary as a treatment of AML in individuals who are in complete marrow and extramedullary remission (CR1 and beyond), and who for medical reasons would be unable to tolerate a myeloablative conditioning regimen.

Autologous HCT may be considered medically necessary in individuals who are not candidates for allogenic HCT to treat AML in CR1 or beyond, or relapsed AML, if responsive to intensified induction chemotherapy.

The use of allogeneic or autologous HCT in individuals to treat AML not meeting the criteria as indicated in this policy is considered not medically necessary.

Risk status of AML based on Genetic Factors

The newer, currently preferred, World Health Organization classification of AML incorporates and interrelates morphology, cytogenetics, molecular genetics, and immunologic markers. It attempts to construct a classification that is universally applicable and prognostically valid. The World Health Organization system was adapted by National Comprehensive Cancer Network to estimate individual, individual's prognosis to guide management, as shown in the below table.

Risk Status

Genetic Abnormalities

Favorable

t(8;21)(q22;q22.1); RUNX1-RUNX1T1 inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 Biallelic mutated CEBPA Mutated NPM1 without FLT3-ITD or with FLT3-ITD^low

Intermediate

Mutated NPM1 and FLT3-ITD^high Wild-type NPM1 withou tFLT3-ITD or with FLT3-ITD^low (without adverse-risk genetic lesions) t(9;11)(p21.3;q23.3); MLLT3-KMT2A Cytogenetic abnormalities not classified as favorable or adverse

Poor/Adverse

t(6;9)(p23;q34.1); DEK-NUP214 t(v;11q23.3); KMT2Arearranged t(9;22)(q34.1;q11.2); BCR-ABL1 inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);GATA2, MECOM(EVI1) -5 or del(5q); -7; -17/abn (17p) Complex karyotype, monosomal karyotype Wild-type NPM1 and FLT3-ITD^high Mutated RUNX1 (if not co-occurring with favorable-risk AML subtypes) Mutated ASXL1 (if not co-occurring with favorable-risk AML subtypes) MutatedTP53

AML: Acute myeloid leukemia; ITD: Internal tandem duplication

Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Allogeneic HCT may be considered medically necessary to treat individuals with markers of poor-risk disease for EITHER of the following conditions:

CLL; or
SLL.

Use of a myeloablative or reduced-intensity pre-transplant conditioning regimen should be individualized based on factors that include individual age, the presence of comorbidities, and disease burden.

Allogeneic HCT to treat CLL or SLL not meeting the criteria as indicated in this policy is considered not medically necessary.

Chronic Myeloid Leukemia (CML)

Allogeneic HCT to treat CML may be considered medically necessary for ANY of the following indications:

Individual has not reached hematologic remission after three (3) months of tyrosine kinase inhibitor (TKI) therapy; or
Lack of cytogenetic response or those individuals in cytogenetic relapse at six (6), 12, or 18 months after achieving initial hematologic remission after three (3) months of TKI therapy; or
Individual has not reached molecular remission by 12 months of TKI therapy; or
Disease progression on TKI therapy has moved to accelerated phase or blast crisis; or
Individual is not a candidate for TKI therapy.

Allogeneic HCT using a reduced-intensity conditioning (RIC) regimen to treat CML may be considered medically necessary for the following:

Individual meets clinical criteria for allogenic HCT but are NOT considered candidates for a myeloablative conditioning HCT:
- Clinical criteria that preclude use of a standard myeloablative conditioning regimen may include but are not limited to:
  - Individuals greater than 60 years of age; or
  - Individuals with comorbidities including but not limited to:
    - Liver or kidney dysfunction; or
    - Generalized debilitation; or
    - Prior intensive chemotherapy; or
    - Low Karnofsky performance status.

Allogeneic HCT to treat CML not meeting the criteria as indicated in this policy is considered not medically necessary.

Hodgkin Lymphoma (HL)

The following HCT treatments may be considered medically necessary for individuals with primary refractory or relapsed HL:

Autologous HCT; or
Allogeneic HCT, using either:
- Myeloablative; or
- Reduced intensity conditioning regimens.

Tandem autologous HCT may be considered medically necessary:

In individuals with primary refractory HL; or
In individuals with relapsed disease with poor risk features who do not attain a complete remission to cytoreductive chemotherapy prior to transplantation.

Autologous or allogeneic HCT to treat Hodgkin lymphoma not meeting the criteria as listed in this policy is considered not medically necessary.

Lugano Classification Staging System for Hodgkin Lymphoma

The staging system used for Hodgkin lymphoma is the Lugano classification. It has four (4) stages, labeled I, II, III, and IV. For limited stage (I or II) HL that affects an organ outside of the lymph system, the letter E is added to the stage (for example, stage IE or IIE).

Stage

Area of Concern

Involvement of a single lymph node region (I) or localized involvement of a single extralymphatic organ or site (I_E).

Involvement of two or more lymph node regions on the same side of the diaphragm (II) or localized involvement of a single associated extralymphatic organ or site and its regional lymph node(s), with or without involvement of other lymph node regions on the same side of the diaphragm (II_E).

III

Involvement of lymph node regions on both sides of the diaphragm (III), which may also be accompanied by localized involvement of an associated extralymphatic organ or site (III_E), by involvement of the spleen (III_S), or by both (III_E+S).

Disseminated (multifocal) involvement of one or more extralymphatic organs, with or without associated lymph node involvement, or isolated extralymphatic organ involvement with distant (nonregional) nodal involvement.

Note: The number of lymph node regions involved may be indicated by a subscript (e.g., II₃).

Each stage may also be assigned a letter (A or B). B is added (stage IIIB, for example) if a person has ANY of these B symptoms:

Loss of more than 10% of body weight over the previous six (6) months (without dieting)
Unexplained fever of at least 100.4F (38C)
Drenching night sweats

If a person has any B symptoms, it usually means the lymphoma is more advanced, and more intensive treatment is often recommended. If no B symptoms are present, the letter A is added to the stage.

PET 5-Point Scale (Deauville Criteria) for Hodgkin Lymphoma

Score

PET/CT Scan Result

Negative

No uptake

Uptake less than or equal to mediastinum

Uptake greater than mediastinum but less than or equal to liver

Positive

Uptake moderately higher than liver and visually above adjacent background activity

Uptake markedly higher than liver and/or new lesions

X^a

New areas of uptake unlikely to be related to lymphoma

^a Watchful waiting, biopsy, or additional imaging tests may be appropriate depending on clinical circumstances. Obtaining a second opinion/overread of the imaging may be beneficial.

Multiple Myeloma (MM)

A single or second (salvage) autologous HCT may be considered medically necessary to treat MM.

Tandem autologous HCT may be considered medically necessary to treat MM in individuals who fail to achieve at least a near-complete or very good partial response after the first transplant in the tandem sequence.

Tandem transplantation with an initial round of autologous HCT followed by a non-marrow-ablative conditioning regimen and allogeneic HCT (i.e., reduced-intensity conditioning (RIC) transplant) may be considered medically necessary to treat newly diagnosed MM individuals.

Autologous HCT, single or tandem, or allogeneic HCT RIC used to treat MM not meeting the criteria as indicated in this policy is considered not medically necessary.

Myelodysplastic Syndromes and Myeloproliferative Neoplasms

Myeloablative allogeneic HCT may be considered medically necessary as a treatment of EITHER of the following conditions:

Myelodysplastic syndromes; or
Myeloproliferative neoplasms.

Reduced-intensity conditioning allogeneic HCT may be considered medically necessary as a risk-adapted treatment in individuals, who for medical reasons would be unable to tolerate a myeloablative conditioning regimen as a treatment of EITHER of the following conditions:

Myelodysplastic syndromes; or
Myeloproliferative neoplasms.

Myeloablative allogeneic HCT or reduced-intensity conditioning allogeneic HCT for myelodysplastic syndromes and myeloproliferative neoplasms not meeting the criteria as indicated in this policy is considered not medically necessary.

Non-Hodgkin Lymphoma (NHL)

Aggressive NHL B-cell Subtype

Allogeneic HCT using a myeloablative conditioning regimen or autologous HCT may be considered medically necessary to treat individuals with aggressive NHL B-cell subtypes (EXCEPT mantle cell lymphoma) for ANY of the following:

As salvage therapy for individuals who do not achieve a complete remission (CR) after first-line treatment (induction) with a full course of standard-dose chemotherapy; or
To achieve or consolidate a CR for those in a chemo-sensitive first or subsequent relapse; or
To consolidate a first CR in individuals with diffuse large B-cell lymphoma, with an age-adjusted International Prognostic Index score that predicts a high- or high-intermediate risk of relapse.

Allogeneic HCT to treat individuals with aggressive NHL B-cell subtypes not meeting the criteria as listed in this policy are considered not medically necessary.

Indolent NHL B-cell Subtype

Allogeneic HCT using a myeloablative conditioning regimen or autologous HCT maybe considered medically necessary to treat individuals with indolent NHL B-cell subtypes for ANY of the following:

As salvage therapy for individuals who do not achieve CR after first-line treatment (induction) with a full course of standard-dose chemotherapy; or
To achieve or consolidate CR for individuals in a first or subsequent chemo sensitive relapse, whether or not their lymphoma has undergone transformation to a higher grade.

Allogeneic HCT to treat individuals with indolent NHL B-cell subtypes not meeting the criteria as listed in this policy are considered not medically necessary.

Mantle Cell Lymphoma

Autologous HCT may be considered medically necessary to consolidate a first remission of mantle cell lymphoma.

Salvage Therapy for Mantle Cell Lymphoma

Allogeneic HCT, myeloablative or reduced-intensity conditioning, used as salvage therapy for mantle cell lymphoma may be considered medically necessary.

HCT to treat mantle cell lymphoma not meeting the criteria as indicated in this policy is considered not medically necessary.

Reduced-intensity conditioning (RIC) allogeneic HCT to treat individuals with NHL may be considered medically necessary for those individuals who meet the above criteria for an allogeneic HCT but who do not qualify for a myeloablative allogeneic HCT.

RIC allogeneic HCT not meeting the criteria to treat NHL as indicated in this policy is considered not medically necessary.

T-Cell Lymphoma

HCT may be considered medically necessary for individuals with mature T-cell or natural killer cell (peripheral T-cell) neoplasms as follows:

Autologous HCT may be considered medically necessary to consolidate a first complete remission in high-risk peripheral T-cell lymphoma.
Autologous or allogeneic HCT (myeloablative or reduced-intensity conditioning) may be considered medically necessary as salvage therapy.

Autologous or allogeneic HCT for treatment of T-cell lymphoma not meeting the criteria as indicated in this policy is considered not medically necessary.

Note: Please see attached table or WHO classification of Non-Hodgkin Lymphomas.

POEMS Syndrome

Autologous HCT to treat disseminated POEMS Syndrome may be considered medically necessary for individuals who are eligible as EITHER:

Sole therapy; or
Consolidation after induction therapy.

Autologous HCT to treat disseminated POEMS Syndrome not meeting the criteria as indicated in this policy is considered not medically necessary.

Primary Systemic Amyloidosis (AL)

Autologous HCT to treat primary systemic AL may be considered medically necessary when ALL the following patient selection criteria are met:

Age greater than 18 years; and
Tissue diagnosis of amyloidosis by:
- Abdominal fat aspirate; or
- Biopsy of involved organ; and
Eastern Cooperative Oncology Group (ECOG) performance status score of zero to two (0- 2); and
New York Heart Association class I/II and no more than two involved major organs (liver, heart, kidney, autonomic nerve); and
Supine systolic blood pressure greater than 90 mm/Hg; and
Asymptomatic or compensated cardiac function including but not limited to:
- Absence of congestive heart failure; and
- Echocardiographic left ejection fraction greater than 40%; and
- Cardiac interventricular septal thickness is greater than 12 mm; and
Renal function with a creatinine clearance of at least 30 ml/min.

Note: When available, a clinical trial should be utilized.

Autologous HCT to treat primary systemic AL not meeting the criteria as indicated in this policy is considered not medically necessary.

Waldenstrom Macroglobulinemia (WM)

Autologous HCT to treat previously treated WM may be considered medically necessary.

Autologous HCT not meeting the criteria as indicated in this policy is considered not medically necessary.

Allogeneic HCT, either ablative or non-ablative, to treat previously treated WM may be considered medically necessary.

Allogeneic HCT to treat previously treated WM not meeting the criteria as indicated in this policy is considered not medically necessary.

Experimental/Investigational

The following conditions for autologous HCT or allogeneic HCT to treat individuals for blood cancers are considered experimental/investigational and therefore, non-covered because the safety and/or effectiveness of this service cannot be established by the available published peer-reviewed literature:

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL):
- Autologous HCT; or
Chronic Myeloid Leukemia (CML):
- Autologous HCT; or
Hodgkin Lymphoma:
- Initial therapy for newly diagnosed disease; or
- To consolidate a first complete remission; or
- Second autologous HCT for relapsed HL after a prior autologous HCT.
Multiple Myeloma (MM):
- Allogeneic HCT, myeloablative or nonmyeloablative
  - Initial therapy of newly diagnosed MM; or
  - Salvage therapy; or
Mantle Cell Lymphoma:
- Autologous HCT used as salvage therapy; or
- Allogeneic HCT to consolidate a first remission of mantle cell lymphoma; or
Non-Hodgkins Lymphoma (NHL):
- Initial therapy for any NHL; or
- To consolidate a first CR for individuals with diffuse large B-cell lymphoma and an International Prognostic Index score that predicts a low- or low-intermediate risk of relapse; or
- To consolidate a first CR for individuals with indolent NHL B-cell subtypes; or
- Tandem HCT to treat individuals with any stage, grade, or subtype of NHL; or
POEMS Syndrome:
- Allogeneic and tandem HCT; or
Primary Systemic Amyloidosis (AL):
- Allogeneic HCT; or
T-Cell Lymphoma:
- Allogeneic HCT to consolidate a first remission.

Allogeneic HCT Procedure Codes

38205

38230

38240

38242

S2140

S2142

S2150

Autologous HCT Procedure Codes

38206

38232

38241

S2150

Donor Leukocyte Infusion

DLI may be considered medically necessary for adults and children following allogeneic HCT that was originally considered medically necessary for the treatment of a hematologic malignancy that has relapsed, or does not respond, to prevent relapse in the setting of a high risk of relapse, or to convert an individual from mixed to full donor chimerism with ANY of the following conditions:

Individuals with acute myeloid leukemia (AML); or
Individuals with chronic myeloid leukemia (CML); or
Individuals with Hodgkin's disease (HD); or
Individuals with acute lymphocytic leukemia (ALL); or
Individuals with multiple myeloma (MM).

DLI not meeting the criteria as indicated in this policy is considered experimental/investigational and therefore non-covered because the safety and/or effectiveness of this services cannot be established by the available published peer-reviewed literature.

Charges for the leukapheresis procedure for the donor are eligible for payment when the donor leukocyte infusion is covered. Payment for eligible donor leukapheresis procedures may be equated to therapeutic apheresis for white blood cells.

Experimental/Investigational

The following procedures concerning DLI are considered experimental/investigational and therefore non-covered because the safety and/or effectiveness of this service cannot be established by the available published peer-reviewed literature:

Genetic or other modification of donor leukocytes

Following allogeneic HCT that was originally considered investigational for the treatment of a hematologic malignancy; or
Treatment of non-hematologic malignancies following a prior allogeneic HCT; or
Other applications of DLI including but not limited to:
- Myelodysplastic syndromes; or
- Non-Hodgkin's lymphoma; or
- Autism spectrum disorder.
- Individuals with:
  - Myelodysplastic syndromes; or
  - Non-Hodgkin's lymphoma; or
  - Autism spectrum disorder.

Procedure Codes

36511

38242

Diagnosis Codes

Acute Lymphoblastic Leukemia

Covered Diagnosis Codes for Procedure Codes: 38205, 38206, 38230, 38232, 38240, 38241, S2140, S2142

C91.00

C91.01

C91.02

Acute Myeloid Leukemia

Covered Diagnosis Codes for Procedure Codes: 38205, 38206, 38230, 38232, 38240, 38241, S2140, S2142, and S2150

C92.00

C92.01

C92.02

C92.40

C92.41

C92.42

C92.50

C92.51

C92.52

C92.60

C92.61

C92.62

C92.A0

C92.A1

C92.A2

C93.00

C93.01

C93.02

C94.00

C94.01

C94.02

C94.20

C94.21

C94.22

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Covered Diagnosis Codes for Procedure Codes: 38205, 38240, S2140, and S2142

C91.10

C91.11

Chronic Myeloid Leukemia

Covered Diagnosis Codes for Procedure Codes: 38205, 38220, 38221, 38222, 38230, 38240, S2140 and S2142

C92.10

C92.12

C92.20

C92.22

Hodgkin Lymphoma

Covered Diagnosis Codes for Procedure Codes: 38205, 38206, 38230, 38232, 38240, 38241, S2140, S2142, and S2150

C81.00

C81.01

C81.02

C81.03

C81.04

C81.05

C81.06

C81.07

C81.08

C81.09

C81.10

C81.11

C81.12

C81.13

C81.14

C81.15

C81.16

C81.17

C81.18

C81.19

C81.20

C81.21

C81.22

C81.23

C81.24

C81.25

C81.26

C81.27

C81.28

C81.29

C81.30

C81.31

C81.32

C81.33

C81.34

C81.35

C81.36

C81.37

C81.38

C81.39

C81.40

C81.41

C81.42

C81.43

C81.44

C81.45

C81.46

C81.47

C81.48

C81.49

C81.70

C81.71

C81.72

C81.73

C81.74

C81.75

C81.76

C81.77

C81.78

C81.79

C81.90

C81.91

C81.92

C81.93

C81.94

C81.95

C81.96

C81.97

C81.98

C81.99

Multiple Myeloma

Covered Diagnosis Codes for Procedure Codes: 38206, 38232, 38241, and S2150

C90.00

C90.02

Myelodysplastic Syndromes and Myeloproliferative Neoplasms

Covered Diagnosis Codes for Procedure Codes: 38205, 38230, 38240, S2140, S2142, and S2150

C88.8

C94.40

C94.41

C94.42

C94.6

D46.0

D46.1

D46.20

D46.21

D46.22

D46.4

D46.9

D46.A

D46.B

D46.C

D46.Z

D47.1

D47.Z9

Non-Hodgkin Lymphoma

Covered Diagnosis Codes for Procedure Codes: 38205, 38206, 38230, 38232, 38240, 38241, S2140, S2142, and S2150

C82.00

C82.01

C82.02

C82.03

C82.04

C82.05

C82.06

C82.07

C82.08

C82.09

C82.10

C82.11

C82.12

C82.13

C82.14

C82.15

C82.16

C82.17

C82.18

C82.19

C82.20

C82.21

C82.22

C82.23

C82.24

C82.25

C82.26

C82.27

C82.28

C82.29

C82.30

C82.31

C82.32

C82.33

C82.34

C82.35

C82.36

C82.37

C82.38

C82.39

C82.40

C82.41

C82.42

C82.43

C82.44

C82.45

C82.46

C82.47

C82.48

C82.49

C82.50

C82.51

C82.52

C82.53

C82.54

C82.55

C82.56

C82.57

C82.58

C82.59

C82.60

C82.61

C82.62

C82.63

C82.64

C82.65

C82.66

C82.67

C82.68

C82.69

C82.80

C82.81

C82.82

C82.83

C82.84

C82.85

C82.86

C82.87

C82.88

C82.89

C82.90

C82.91

C82.92

C82.93

C82.94

C82.95

C82.96

C82.97

C82.98

C82.99

C83.00

C83.01

C83.02

C83.03

C83.04

C83.05

C83.06

C83.07

C83.08

C83.09

C83.10

C83.11

C83.12

C83.13

C83.14

C83.15

C83.16

C83.17

C83.18

C83.19

C83.30

C83.31

C83.32

C83.33

C83.34

C83.35

C83.36

C83.37

C83.38

C83.39

C83.50

C83.51

C83.52

C83.53

C83.54

C83.55

C83.56

C83.57

C83.58

C83.59

C83.70

C83.71

C83.72

C83.73

C83.74

C83.75

C83.76

C83.77

C83.78

C83.79

C83.80

C83.81

C83.82

C83.83

C83.84

C83.85

C83.86

C83.87

C83.88

C83.89

C83.90

C83.91

C83.92

C83.93

C83.94

C83.95

C83.96

C83.97

C83.98

C83.99

C84.40

C84.41

C84.42

C84.43

C84.44

C84.45

C84.46

C84.47

C84.48

C84.49

C84.60

C84.61

C84.62

C84.63

C84.64

C84.65

C84.66

C84.67

C84.68

C84.69

C84.70

C84.71

C84.72

C84.73

C84.74

C84.75

C84.76

C84.77

C84.78

C84.79

C84.90

C84.91

C84.92

C84.93

C84.94

C84.95

C84.96

C84.97

C84.98

C84.99

C84.A0

C84.A1

C84.A2

C84.A3

C84.A4

C84.A5

C84.A6

C84.A7

C84.A8

C84.A9

C84.Z0

C84.Z1

C84.Z2

C84.Z3

C84.Z4

C84.Z5

C84.Z6

C84.Z7

C84.Z8

C84.Z9

C85.10

C85.11

C85.12

C85.13

C85.14

C85.15

C85.16

C85.17

C85.18

C85.19

C85.20

C85.21

C85.22

C85.23

C85.24

C85.25

C85.26

C85.27

C85.28

C85.29

C85.80

C85.81

C85.82

C85.83

C85.84

C85.85

C85.86

C85.87

C85.88

C85.89

C85.90

C85.91

C85.92

C85.93

C85.94

C85.95

C85.96

C85.97

C85.98

C85.99

C86.0

C86.1

C86.2

C86.3

C86.4

C86.5

C86.6

C88.4

POEMS

Covered Diagnosis Codes for Procedure Codes: 38206, 38232, 38241, and S2150

D47.Z9

Primary Systemic Amyloidosis

Covered Diagnosis Codes for Procedure Codes: 38206, 38232, 38241, S2150

E85.81

Waldenström Macroglobulinemia

Covered Diagnosis Code for Procedure Codes:

C88.0

Donor Leukocyte Infusion

Covered Diagnosis Codes for Procedure Code: 38242

C81.00

C81.01

C81.02

C81.03

C81.04

C81.05

C81.06

C81.07

C81.08

C81.09

C81.10

C81.11

C81.12

C81.13

C81.14

C81.15

C81.16

C81.17

C81.18

C81.19

C81.20

C81.21

C81.22

C81.23

C81.24

C81.25

C81.26

C81.27

C81.28

C81.29

C81.30

C81.31

C81.32

C81.33

C81.34

C81.35

C81.36

C81.37

C81.38

C81.39

C81.40

C81.41

C81.42

C81.43

C81.44

C81.45

C81.46

C81.47

C81.48

C81.49

C81.70

C81.71

C81.72

C81.73

C81.74

C81.75

C81.76

C81.77

C81.78

C81.79

C81.90

C81.91

C81.92

C81.93

C81.94

C81.95

C81.96

C81.97

C81.98

C81.99

C90.00

C90.01

C90.02

C91.00

C91.01

C91.02

C91.10

C91.11

C91.12

C91.30

C91.31

C91.32

C91.50

C91.51

C91.52

C91.60

C91.61

C91.62

C91.90

C91.91

C91.92

C91.A0

C91.A1

C91.A2

C91.Z0

C91.Z1

C91.Z2

C92.00

C92.01

C92.02

C92.10

C92.11

C92.12

C92.20

C92.21

C92.22

C92.30

C92.31

C92.32

C92.40

C92.41

C92.42

C92.50

C92.51

C92.52

C92.60

C92.61

C92.62

C92.90

C92.91

C92.92

C92.A0

C92.A1

C92.A2

C92.Z0

C92.Z1

C92.Z2

Non-Covered Diagnosis Codes for Procedure Code: 38242

C82.00

C82.01

C82.02

C82.03

C82.04

C82.05

C82.06

C82.07

C82.08

C82.09

C82.10

C82.11

C82.12

C82.13

C82.14

C82.15

C82.16

C82.17

C82.18

C82.19

C82.20

C82.21

C82.22

C82.23

C82.24

C82.25

C82.26

C82.27

C82.28

C82.29

C82.30

C82.31

C82.32

C82.33

C82.34

C82.35

C82.36

C82.37

C82.38

C82.39

C82.40

C82.41

C82.42

C82.43

C82.44

C82.45

C82.46

C82.47

C82.48

C82.49

C82.50

C82.51

C82.52

C82.53

C82.54

C82.55

C82.56

C82.57

C82.58

C82.59

C82.60

C82.61

C82.62

C82.63

C82.64

C82.65

C82.66

C82.67

C82.68

C82.69

C82.80

C82.81

C82.82

C82.83

C82.84

C82.85

C82.86

C82.87

C82.88

C82.89

C82.90

C82.91

C82.92

C82.93

C82.94

C82.95

C82.96

C82.97

C82.98

C82.99

C83.00

C83.01

C83.02

C83.03

C83.04

C83.05

C83.06

C83.07

C83.08

C83.09

C83.10

C83.11

C83.12

C83.13

C83.14

C83.15

C83.16

C83.17

C83.18

C83.19

C83.30

C83.31

C83.32

C83.33

C83.34

C83.35

C83.36

C83.37

C83.38

C83.39

C83.50

C83.51

C83.52

C83.53

C83.54

C83.55

C83.56

C83.57

C83.58

C83.59

C83.70

C83.71

C83.72

C83.73

C83.74

C83.75

C83.76

C83.77

C83.78

C83.79

C83.80

C83.81

C83.82

C83.83

C83.84

C83.85

C83.86

C83.87

C83.88

C83.89

C83.90

C83.91

C83.92

C83.93

C83.94

C83.95

C83.96

C83.97

C83.98

C83.99

C84.40

C84.41

C84.42

C84.43

C84.44

C84.45

C84.46

C84.47

C84.48

C84.49

C84.60

C84.61

C84.62

C84.63

C84.64

C84.65

C84.66

C84.67

C84.68

C84.69

C84.70

C84.71

C84.72

C84.73

C84.74

C84.75

C84.76

C84.77

C84.78

C84.79

C84.90

C84.91

C84.92

C84.93

C84.94

C84.95

C84.96

C84.97

C84.98

C84.99

C84.A0

C84.A1

C84.A2

C84.A3

C84.A4

C84.A5

C84.A6

C84.A7

C84.A8

C84.A9

C84.Z0

C84.Z1

C84.Z2

C84.Z3

C84.Z4

C84.Z5

C84.Z6

C84.Z7

C84.Z8

C84.Z9

C85.10

C85.11

C85.12

C85.13

C85.14

C85.15

C85.16

C85.17

C85.18

C85.19

C85.20

C85.21

C85.22

C85.23

C85.24

C85.25

C85.26

C85.27

C85.28

C85.29

C85.80

C85.81

C85.82

C85.83

C85.84

C85.85

C85.86

C85.87

C85.88

C85.89

C85.90

C85.91

C85.92

C85.93

C85.94

C85.95

C85.96

C85.97

C85.98

C85.99

C86.0

C86.1

C86.2

C86.3

C86.4

C86.5

C86.6

C88.4

D46.0

D46.1

D46.20

D46.21

D46.22

D46.4

D46.9

D46.A

D46.B

D46.C

D46.Z

F84.0

F84.3

F84.5

F84.8

F84.9

Professional Statements and Societal Positions Guidelines

National Comprehensive Cancer Network - 2022

ND Committee Review

Internal Medical Policy Committee 7-21-2022 New Policy consisting of a combination of the following policies

S-206 Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma; and
S-207 Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma; and
S-208 Hematopoietic Cell Transplantation for Non-Hodgkin Lymphomas; and
S-209 Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms; and
S-214 Hematopoietic Cell Transplantation for Acute Myeloid Leukemia; and
S-217 Hematopoietic Cell Transplantation for Hodgkin Lymphoma; and
S-218 Hematopoietic Cell Transplantation for Chronic Myeloid Leukemia; and
S-220 Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia; and
S-223 Hematopoietic Cell Transplantation for Primary Amyloidosis; and
S-224 Hematopoietic Cell Transplantation for Waldenström Macroglobulinemia; and
S-143 Donor Leukocyte Infusion for Hematologic Malignancies that Relapse after Allogeneic Cell Transplant

Internal Medical Policy Committee 5-23-2023 Annual Review - no changes in criteria

Internal Medical Policy Committee 5-14-2024 Annual Review - no changes in criteria

Added Policy Application

Links

References (PDF)

Disclaimer

Current medical policy is to be used in determining a Member's contract benefits on the date that services are rendered. Contract language, including definitions and specific inclusions/exclusions, as well as state and federal law, must be considered in determining eligibility for coverage. Members must consult their applicable benefit plans or contact a Member Services representative for specific coverage information. Likewise, medical policy, which addresses the issue(s) in any specific case, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and the Company reserves the right to review and update medical policy periodically.

Our Partners in Health:
Members
Employers
Producers

Fargo (Headquarters)
4510 13th Ave. S.
Fargo, N.D., 58121

Medical Policies Quick Search

Hematopoietic Cell Transplantation: Blood Cancers

Description

Policy Application

Criteria

Allogeneic HCT Procedure Codes

Autologous HCT Procedure Codes

Procedure Codes

Diagnosis Codes

Professional Statements and Societal Positions Guidelines

ND Committee Review

Links

Disclaimer